Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
34 Results for "
KMT2
" in MedChemExpress (MCE) Product Catalog:
Products (34)
34 Results for "KMT2" in MCE Product Catalog:
2
2 Cited Publications
Synonyms: JNJ-75276617; Menin-MLL inhibitor 24
Target:
Research Areas:
Bleximenib (JNJ-75276617) is an orally active and selective menin-KMT2A inhibitor, with IC50 values of 0.1 nM, 0.045 nM, and ≤0.066 nM for humans, mice, and dogs, respectively. Bleximenib can inhibit the proliferation and induce apoptosis and differentiation of tumor cells. Bleximenib can be used in the research of tumors such as leukemia [2].
2
2 Cited Publications
Synonyms: JNJ-75276617 oxalate; Menin-MLL inhibitor 24 oxalate
Target:
Research Areas:
Bleximenib (JNJ-75276617) oxalate is an orally active and selective menin-KMT2A inhibitor, with IC50 values of 0.1 nM, 0.045 nM, and ≤0.066 nM for humans, mice, and dogs, respectively. Bleximenib oxalate can inhibit the proliferation and induce apoptosis and differentiation of tumor cells. Bleximenib oxalate can be used in the research of tumors such as leukemia [2].
Synonyms: DSP-5336
Target:
Research Areas:
Enzomenib (DSP-5336) is an orally active Menin inhibitor (IC50=1.4 nM, Kd=6.0 nM). Enzomenib disrupts the interaction between Menin and KMT2A/MLL fusion proteins, specifically inhibits the expression of leukemia driver genes such as HOX/MEIS1, and upregulates ITGAM. Enzomenib effectively induces cell differentiation, inhibits tumor cell proliferation, and suppresses primitive cell colony formation. Enzomenib reduces disease burden and prolongs survival, but causes adverse reactions including differentiation syndrome and QTc interval prolongation. Enzomenib is used for research on relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, and other hematologic malignancies with mixed lineage leukemia (MLL) rearrangements or NPM1 mutations [2] .
Cat. No.: HY-172416
CAS No.: 2939850-17-4
Synonyms: ZE63-0302
Target:
Research Areas:
Balomenib (ZE63-0302) is an orally bioavailable menin-KMT2A interaction inhibitor. Balomenib disrupts menin-KMT2A binding, reverses aberrant HOX gene expression. Balomenib inhibits Meis1 mRNA expression in KMT2A-rearranged acute myeloid leukemia cells. Balomenib can be used for the research of leukemia .
Cat. No.: HY-RS07403
Target:
Research Areas:
KMT2C Human Pre-designed siRNA Set A contains three designed siRNAs for KMT2C gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS07404
Target:
Research Areas:
KMT2D Human Pre-designed siRNA Set A contains three designed siRNAs for KMT2D gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-148669B
Purity: 98.37%
Synonyms: (S)-JNJ-75276617 oxalate; (S)-Menin-MLL inhibitor 24 oxalate
Target:
Research Areas:
(S)-Bleximenib (oxalate) is a S-Enantiomer of Bleximenib oxalate (HY-148669A). Bleximenib (JNJ-75276617) oxalate is an orally active and selective menin-KMT2A inhibitor, with IC50 values of 0.1 nM, 0.045 nM, and ≤0.066 nM for humans, mice, and dogs, respectively. Bleximenib oxalate can inhibit the proliferation and induce apoptosis and differentiation of tumor cells. Bleximenib oxalate can be used in the research of tumors such as leukemia .
Cat. No.: HY-170832
Research Areas:
Menin–KMT2A-IN-1 (Compound 20) is the inhibitor for menin–KMT2A that binds to menin with an IC50 of 8 nM, and inhibits the interaction between menin and lysine methyltransferase 2A (KMT2A). Menin–KMT2A-IN-1 inhibits hERG with an IC50 of 65 μM. Menin–KMT2A-IN-1 inhibits cell MV4-11 with an IC50 of 74 nM. Menin–KMT2A-IN-1 exhibits good pharmacokinetic characteristics in CD-1 mouse with an orally bioavailability of 74% .
Cat. No.: HY-RS07401
Target:
Research Areas:
KMT2A Human Pre-designed siRNA Set A contains three designed siRNAs for KMT2A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS18528
Target:
Research Areas:
Kmt2a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Kmt2a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS25010
Target:
Research Areas:
Kmt2a Rat Pre-designed siRNA Set A contains three designed siRNAs for Kmt2a gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS07402
Target:
Research Areas:
KMT2B Human Pre-designed siRNA Set A contains three designed siRNAs for KMT2B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS07405
Target:
Research Areas:
KMT2E Human Pre-designed siRNA Set A contains three designed siRNAs for KMT2E gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS17767
Target:
Research Areas:
Kmt2d Mouse Pre-designed siRNA Set A contains three designed siRNAs for Kmt2d gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS20048
Target:
Research Areas:
Kmt2c Mouse Pre-designed siRNA Set A contains three designed siRNAs for Kmt2c gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS24234
Target:
Research Areas:
Kmt2d Rat Pre-designed siRNA Set A contains three designed siRNAs for Kmt2d gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS26552
Target:
Research Areas:
Kmt2c Rat Pre-designed siRNA Set A contains three designed siRNAs for Kmt2c gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS20975
Target:
Research Areas:
Kmt2b Mouse Pre-designed siRNA Set A contains three designed siRNAs for Kmt2b gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS27492
Target:
Research Areas:
Kmt2b Rat Pre-designed siRNA Set A contains three designed siRNAs for Kmt2b gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-P703634
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: HALR; KIAA1506; MLL3
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
